Still calculating financial ratios manually?
Stop wasting time — let the computer do it!
Silo Pharma, Inc. (SILO) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
677 N. WASHINGTON BLVD SARASOTA, FL 34236 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2026 Q1 | 12/31/2025 Q4 | 9/30/2025 Q3 | 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 6,859 | 5,866 | 6,260 | 5,451 | 7,081 | 8,015 | |||
| Cash and cash equivalent | 4,749 | 3,918 | 4,334 | 3,137 | 3,906 | 4,861 | |||
| Short-term investments | 2,110 | 1,949 | 1,926 | 2,315 | 3,175 | 3,154 | |||
| Deferred costs | 261 | 261 | |||||||
| Other current assets | 99 | ||||||||
| Other undisclosed current assets | 169 | 37 | 113 | 153 | 31 | 246 | |||
| Total current assets: | 7,388 | 6,164 | 6,373 | 5,604 | 7,111 | 8,262 | |||
| Noncurrent Assets | |||||||||
| Intangible asset, including goodwill, after accumulated amortization | 217 | 220 | 223 | 238 | 241 | 244 | |||
| Intangible asset, excluding goodwill, after accumulated amortization | 217 | 220 | 223 | 238 | 241 | 244 | |||
| Other undisclosed noncurrent assets | 56 | 58 | 59 | 61 | |||||
| Total noncurrent assets: | 217 | 220 | 279 | 296 | 300 | 305 | |||
| TOTAL ASSETS: | 7,605 | 6,385 | 6,653 | 5,900 | 7,412 | 8,567 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 578 | 636 | 978 | 1,113 | 1,584 | 973 | |||
| Accrued liabilities | 60 | ||||||||
| Other undisclosed accounts payable and accrued liabilities | 578 | 636 | 978 | 1,113 | 1,524 | 973 | |||
| Deferred revenue | 72 | 72 | 72 | 72 | 72 | 72 | |||
| Total current liabilities: | 650 | 708 | 1,050 | 1,185 | 1,656 | 1,045 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 649 | 668 | 686 | 704 | 722 | 740 | |||
| Deferred revenue | 649 | 668 | 686 | 704 | 722 | 740 | |||
| Total noncurrent liabilities: | 649 | 668 | 686 | 704 | 722 | 740 | |||
| Total liabilities: | 1,300 | 1,376 | 1,735 | 1,889 | 2,378 | 1,784 | |||
| Equity | |||||||||
| Equity, attributable to parent | 6,305 | 5,009 | 4,917 | 4,011 | 5,034 | 6,782 | |||
| Common stock | 1 | 1 | 1 | 0 | 0 | 0 | |||
| Treasury stock, value | (6) | ||||||||
| Additional paid in capital | 25,791 | 23,607 | 22,407 | 20,296 | 20,296 | 20,302 | |||
| Accumulated other comprehensive income | 6 | 11 | 10 | 11 | 2 | 20 | |||
| Accumulated deficit | (19,492) | (18,611) | (17,500) | (16,296) | (15,265) | (13,534) | |||
| Total equity: | 6,305 | 5,009 | 4,917 | 4,011 | 5,034 | 6,782 | |||
| TOTAL LIABILITIES AND EQUITY: | 7,605 | 6,385 | 6,653 | 5,900 | 7,412 | 8,567 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2026 Q1 | 12/31/2025 Q4 | 9/30/2025 Q3 | 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 18 | 18 | 18 | 18 | 18 | 18 | ||
| Realized investment gains | 1 | 3 | ||||||
| Cost of revenue | (21) | (21) | (1) | (1) | (1) | (1) | ||
| Gross profit: | (3) | (3) | 17 | 17 | 17 | 17 | ||
| Operating expenses | (784) | (1,149) | (1,265) | (1,111) | (1,830) | (1,027) | ||
| Operating loss: | (787) | (1,151) | (1,249) | (1,094) | (1,813) | (1,010) | ||
| Nonoperating income (expense) | (95) | 41 | 44 | 63 | 83 | 81 | ||
| Investment income, nonoperating | 43 | 45 | 45 | 62 | 83 | 85 | ||
| Interest and debt expense | (33) | (1) | (2) | (2) | (0) | (1) | ||
| Loss from continuing operations before equity method investments, income taxes: | (914) | (1,111) | (1,206) | (1,034) | (1,731) | (930) | ||
| Other undisclosed income from continuing operations before income taxes | 33 | 1 | 2 | 2 | 0 | 1 | ||
| Net loss available to common stockholders, diluted: | (882) | (1,110) | (1,204) | (1,031) | (1,731) | (929) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2026 Q1 | 12/31/2025 Q4 | 9/30/2025 Q3 | 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (882) | (1,110) | (1,204) | (1,031) | (1,731) | (929) | ||
| Comprehensive loss: | (882) | (1,110) | (1,204) | (1,031) | (1,731) | (929) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (6) | 2 | (1) | 8 | (17) | 12 | ||
| Comprehensive loss, net of tax, attributable to parent: | (887) | (1,109) | (1,205) | (1,023) | (1,748) | (917) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.
An easy way to get professional financial analysis in one click
Load financial statements → click "Get report" → Your report is ready.
No financial analysis knowledge required!